GrimesDA. Venous thromboembolism and desogestrelor gestodene-containing combination oral contraceptives: what are the facts?Contraception Rep1996; 7 (1)1–15.
2.
FarmerR. Safety of modern oral contraceptives (letter). Lancet1996; 347: 259.
3.
PersaudR. Oral contraceptives and venous thromboembolism (letter). Lancet1995; 346: 1430–1.
4.
FrancombeH. Pill's risk not to be taken lightly: study. Aust Doctor2000; (June 30):3.
5.
New Zealand Ministry of Health: media release March 3, 1999. Ministry advice on pill consistent, consensual and commonsense. www.moh.govt.nz (accessed 2003 Feb 5).
GrimesDA. Desogestrel-and gestodene-containing combination OC's and venous thromboembolism: where are we now?Contraception Rep1999; 10 (1): 4–8.
8.
McPhersonK. Third generation oral contraception and venous thromboembolism. BMJ1996; 312: 68–9.
9.
GrantEC. Dangers of suppressing menstruation (letter). Lancet2000; 356: 513.
10.
AshrafH. UK high court dismisses risk of VTE in “pill” test case. Lancet2002; 360: 391.
11.
SkeggCG. Pitfalls of pharmacoepidemiology. BMJ2000; 321: 1171–2.
12.
van HeterenG. Wyeth suppresses research on pill. Programme claims (letter). BMJ2001; 322: 571.
13.
BrockP. Wyeth responds to news story on oral contraceptives and DVT (letter). BMJ2001; 322: 1605.
14.
LidegaardOEdstromBKreinerS. Oral contraceptives and venous thromboembolism. Contraception1998; 57: 291–301.
15.
LawrensonRAWhalleyASimpsonEFarmerRDT. DoH seems to have underestimated incidence of venous thromboembolism in users of combined oral contraceptives (letter). BMJ1999; 319: 387.
16.
WeissG. Risk of venous thromboembolism with third-generation contraceptives: a review. Am J Obstet Gynecol1999; 180:(2 pt 2): S295–301.
17.
GreerIA. Thrombosis in pregnancy: maternal and fetal issues. Lancet1999; 353: 1258–65.
18.
VandenbrouckeJPHelmerhorstFMBloemenkampKWMRosendaalFR. Third-generation oral contraceptive and deep venous thrombosis: from epidemiologic controversy to new insight in coagulation. Am J Obstet Gynecol1997; 177: 887–91.
19.
HeringsRMCUrquhartJLeufkensHGM. Venous thromboembolism among new users of different oral contraceptives. Lancet1999; 354: 127–8.
VandenbrouckeJPBloemenkampKWMMiddeldorpSHelmerhorstFMBoumaBNRosendaalFR. Oral contraceptives and the risk of venous thrombosis. N Engl J Med2001; 344: 1527–1535.
22.
SpitzerWOLewisMAHeinemannLAThorogoodMMacRaeKD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case–control study. BMJ1996; 31; 83–8.
23.
HagueWMNorthRAGallusASWaltersBNOrlikowskiCBurrowsRF, Anticoagulation in pregnancy and the puerperium. Med J Aust2001; 175: 258–63.
24.
RosingJMiddledorpSCurversJChristellaMThomassenLGDNicolaesGA, Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet1999; 354: 2036–40.
25.
SuissaSBlaisLSpitzerWOCussonJLewisMHeinemannL. First-ever use of newer oral contraceptives and the risk of venous thromboembolism. Contraception1997; 56: 141–6.
26.
FarmerRDTWilliamsTJSimpsonELNightingaleAL. Effect of the 1995 pill scare on rates of venous thromboembolism among women taking combined oral contraceptives: analysis of General Practice Research Database. BMJ2000; 321: 477–9.
SorensenMBCollinsPOngPJLWebbCMHaywardCSAsburyEA, Long-term use of contraceptive depot medroxyprogesterone acetate in young women impairs arterial endothelial function assessed by cardiovascular magnetic resonance. Circulation2002; 106: 1646–51.
29.
TangOSTangGYipPLiBFanS. Long-term depot-medroxyprogesterone acetate and bone mineral density. Contraception1999; 59: 25–9.
30.
LarimoreWLStanfordJB. Postfertilization effects of oral contraceptives and their relationship to informed consent. Arch Family Med2000; 9: 126–33.
31.
A prospective multi-centre trial of ovulation method of natural family planning. II. The effectiveness phase. Fert Steril1981; 36: 591–8.
32.
FuHDarrochJEHaasTRanjitN. Contraceptive failure rates: new estimates from the 1995 National Survey of Family Growth. Fam Plann Perspect1999; 31: 56–63.